MIM
ALNY icon

MetLife Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

MetLife Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Sell
7,410
-390
-5% -$118K 0.01% 1090
2026
Q1 		$2.58M Sell
7,800
-387
-5% -$132K 0.01% 926
2025
Q4 		$3.26M Buy
8,187
+195
+2% +$86.3K 0.02% 825
2025
Q3 		$3.64M Buy
7,992
+231
+3% +$94.1K 0.02% 783
2025
Q2 		$2.53M Buy
7,761
+466
+6% +$129K 0.01% 883
2025
Q1 		$1.97M Sell
7,295
-9
-0.1% -$2.31K 0.01% 1044
2024
Q4 		$1.72M Sell
7,304
-14
-0.2% -$3.68K 0.01% 1122
2024
Q3 		$2.01M Sell
7,318
-144
-2% -$37.5K 0.01% 1016
2024
Q2 		$1.81M Buy
7,462
+856
+13% +$135K 0.01% 1017
2024
Q1 		$987K Buy
6,606
+102
+2% +$17K 0.01% 1308
2023
Q4 		$1.24M Sell
6,504
-92
-1% -$15.7K 0.01% 1185
2023
Q3 		$1.17M Buy
6,596
+4
+0.1% +$763 0.01% 1155
2023
Q2 		$1.25M Sell
6,592
-858
-12% -$170K 0.01% 1142
2023
Q1 		$1.49M Buy
7,450
+18
+0.2% +$3.78K 0.01% 1023
2022
Q4 		$1.77M Sell
7,432
-58
-0.8% -$12.4K 0.01% 955
2022
Q3 		$1.5M Buy
7,490
+5
+0.1% +$954 0.01% 1000
2022
Q2 		$1.09M Sell
7,485
-278
-4% -$39.4K 0.01% 1166
2022
Q1 		$1.27M Buy
+7,763
New +$1.18M 0.01% 1191
2019
Q2 		– Sell
-387
Closed -$36.1K – 2432
2019
Q1 		$36.1K Buy
387
+265
+217% +$22.2K ﹤0.01% 2377
2018
Q4 		$8.89K Sell
122
-1
-0.8% -$77 ﹤0.01% 2389
2018
Q3 		$10.8K Buy
+123
New +$12.4K ﹤0.01% 2431

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's ALNY Position: Q2 2026 in Review

MetLife Investment Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 5% in Q2 2026, selling an estimated $118K and leaving 7,410 shares worth $2.23M. The position accounts for 0.01% of the portfolio, ranked #1090.

MetLife Investment Management first reported a position in ALNY in Q3 2018 and has held it in 21 quarters since. The position peaked at $3.64M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • MetLife Investment Management held 7,410 shares of Alnylam Pharmaceuticals worth $2.23M as of Q2 2026.
  • MetLife Investment Management sold 390 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $118K.
  • Alnylam Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1090 holding.
  • MetLife Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 21 quarters since.
  • MetLife Investment Management's Alnylam Pharmaceuticals position peaked at $3.64M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.